SolventumSOLV

UBS raised its price target to $101 from $95. This is a notable move from a major firm, signaling that the company's recent performance and its plan to separate its software division are being well-received.

For a long-term owner, this shows that professional analysts are becoming more optimistic about the company's ability to grow as a more focused medical technology business. The target suggests the stock could rise about 20 percent from where it is today.

Source: UBS

Mizuho Securities raised its price target to $113 from $100. This is one of the more aggressive targets among major firms, sitting well above the average analyst target of $91.

This move suggests that Mizuho sees the company's plan to shed its hospital software business as a major step toward becoming a more profitable, pure-play medical device company. A target this high implies the firm believes the stock is significantly undervalued at its current price.

Source: Mizuho Securities

Solventum reported adjusted earnings of $2.55 per share, which was much higher than the $1.90 analysts expected. Revenue reached about $2.21 billion, also beating targets. The company saw strong organic growth, which measures sales from its existing businesses excluding things like currency swings or acquisitions, of nearly 10 percent.

The biggest news is the plan to separate its Health Information Systems business, which makes software for hospitals. This move is designed to leave behind a more focused medical technology company that can grow faster. Management also raised its full-year outlook for sales, profits, and cash flow, signaling that the business is performing better than they initially thought it would after spinning off from 3M.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

The company filed an 8-K, a form used to report major events to the SEC, regarding a change in its executive team or board of directors. These filings are standard when a leader joins or leaves a company.

For a business still in the early stages of its life as an independent company, leadership stability is important. While the filing itself is a routine requirement, it ensures that investors are kept informed about who is steering the company's turnaround strategy.

Source: 8-K filing

Key highlights

• Profit outlook raised: Management raised its full year profit forecast to a range between $7.10 and $7.20 per share, up from the previous top end of $6.60. This increase reflects better performance in the core business and higher expected cash flow, which is now predicted to be between $200 million and $300 million.
• Dental segment surge: The dental solutions business grew organic sales, which excludes the impact of currency and big business deals, by 15.2% this quarter. This was a major jump from the 9.4% growth seen in the first half of the year, driven by higher demand and volume for dental and orthodontic products.
• Operating margins expanding: Adjusted operating margins, a measure of how much profit is left after paying for business operations, reached 28.4% compared to 21.9% a year ago. A one time refund on import taxes and better efficiency helped drive this 650 basis point improvement.
• Major division separation: The company announced it will separate its Health Information Systems business, which grew organic sales by 5.4% this quarter to reach $354 million. This move is designed to make the company a more focused medical technology business by shedding the software and data visualization arm.
• Broad organic growth: Total organic sales grew 9.5% in the quarter, though some of this was due to customers placing early orders for $2.21 billion in products ahead of a technology system update. Even without these early orders, every main business segment reported growth for the period.

Our take: A very strong quarter that shows the business is running much more efficiently as an independent company. The massive jump in profit guidance and the plan to spin off the software division signal that management is moving quickly to unlock value. This performance reinforces the case for owning the stock long term.